Hedera Dx participates in the Swiss artificial intelligence initiative NAIPO

Hedera Dx is proud to announce its participation in the National Artificial Intelligence Initiative for Precision Oncology (NAIPO), a significant Innosuisse programme. The initiative is led by EPFL AI Center and ETH AI Center and brings together leading academic institutions, hospitals, and industry partners across Switzerland.

NAIPO aims to transform cancer care by developing AI-driven solutions that integrate multimodal patient data, including genomics, pathology, and clinical information, to enable more precise, personalized treatment decisions. By combining cutting-edge research with clinical implementation, the initiative seeks to improve patient outcomes while addressing the growing complexity and cost of oncology care.

As part of this national consortium, Hedera Dx contributes its expertise in liquid biopsy technologies and artificial intelligence. These approaches play a key role in the development of clinically grounded AI models for precision oncology.

Through this collaboration, Hedera Dx joins a broad network of partners working to build a secure, scalable infrastructure for AI-powered oncology and to accelerate the translation of innovation into clinical practice. We are excited to contribute to this initiative and to help shape the future of precision medicine.